Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Dann, Eldad J.; Bar‐Shalom, Rachel; Tamir, Ada; Haim, Nissim; Ben-Shachar, Menachem; Avivi, Irit; Zuckerman, Tzila; Kirschbaum, Mark; Goor, Odelia; Libster, Diana; Rowe, Jacob M.; Epelbaum, Ron

doi:10.1182/blood-2006-04-019901

Cited by 117 publications

(72 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Risk-adapted treatment of Hodgkin's lymphoma has recently been evaluated in a phase II study by Dann et al (60). These investigators used 18 F-FDG PET/CT to adjust treatment after 2 cycles of chemotherapy (60).…”

Section: Clinical Applicationsmentioning

confidence: 99%

Tumor Cell Metabolism Imaging

Plathow¹,

Weber²

2008

J Nucl Med

278

222

View full text Add to dashboard Cite

Molecular imaging of tumor metabolism has gained considerable interest, since preclinical studies have indicated a close relationship between the activation of various oncogenes and alterations of cellular metabolism. Furthermore, several clinical trials have shown that metabolic imaging can significantly impact patient management by improving tumor staging, restaging, radiation treatment planning, and monitoring of tumor response to therapy. In this review, we summarize recent data on the molecular mechanisms underlying the increased metabolic activity of cancer cells and discuss imaging techniques for studies of tumor glucose, lipid, and amino acid metabolism.

show abstract

Section: Clinical Applicationsmentioning

confidence: 99%

Tumor Cell Metabolism Imaging

Plathow¹,

Weber²

2008

J Nucl Med

278

222

View full text Add to dashboard Cite

show abstract

“…62,63 Limited and preliminary reports from a retrospective study 64 and a prospective trial, 65 have demonstrated an apparent advantage with respect to failure-free survival using a PET-adapted strategy as compared with the conventional treatment schedule. However, no direct randomized comparison is currently available comparing a PET response-adapted strategy versus the standard chemotherapy regimen without any alteration during treatment.…”

Section: Interim Pet Outside Clinical Trials: Problems and Interpretamentioning

confidence: 99%

Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?

Gallamini

Kostakoğlu

2012

Blood

View full text Add to dashboard Cite

“…[12][13][14][15][16][17][18] Numerous studies have been published over the past decade regarding the clinical utility of FDG-PET/CT in the management of HL. [14][15][16][17][18][19][20][21][22] These include important data that have been produced regarding the standardization of the reproducibility and interpretability of FDG-PET/CT, which are critical for the appropriate incorporation of this modality into routine clinical practice. In addition, observational and noncontrolled prospective studies have generated hypotheses supporting the concept of early (interim) risk assessment using FDG-PET/CT imaging for prognostication and prediction of outcome.…”

Section: Introductionmentioning

confidence: 99%

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Evens

Kostakoğlu

2014

Blood

View full text Add to dashboard Cite

Given the excellent survival rates for early-stage Hodgkin lymphoma (HL), the young age of many patients, and concerns regarding acute and late treatment-related toxicities, there is a desire to have a predictive tool that enables therapy to be tailored toward the individual patient. Early (or interim) 18F-fluorodeoxyglucose positron emission tomography with computerized tomography (FDG-PET/CT), as a test of tumor sensitivity to ongoing/planned therapy, has been shown to be prognostic for survival in HL. Based on results of interim FDG-PET/CT, therapy may be subsequently modified through minimization or via intensification for low- and high-risk patient populations, respectively (ie, response-adapted therapy). Important data have been generated to standardize the interpretability and reproducibility of interim FDG-PET/CT (eg, the Deauville 5-point system), and observational and noncontrolled prospective studies have produced evidence supporting the hypothesis that response-adapted therapy may potentially serve as a predictive tool. Furthermore, results from noninferiority phase 3 clinical trials randomizing early-stage HL patients with negative interim FDG-PET/CT to combined modality therapy versus chemotherapy alone have been reported. The current collective findings from these randomized early-stage HL studies have shown that acute relapse rates are lower with combined modality therapy, even in patients with negative interim FDG-PET/CT. Additional randomized response-adapted studies are ongoing and novel FDG-PET/CT applications involving quantitative techniques and innovative imaging modalities are being investigated to identify more robust imaging biomarkers. Treatment of early-stage HL remains a clinical management choice for physicians and patients to make with consideration of acute and long-term outcomes.

show abstract

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Abstract: Therapy of Hodgkin disease (HD) is de-

Cited by 117 publications

References 18 publications

Tumor Cell Metabolism Imaging

Tumor Cell Metabolism Imaging

Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Contact Info

Product

Resources

About